Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial comparing pharmacokinetics and pharmacodynamics of BI 695500 versus Rituximab as first-line treatment in low tumor burden follicular lymphoma; com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• BI 695500
• Rituximab (rituximab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lymphoma, Follicular | Phase 1 | Status: COMPLETED | Results posted: 2018-09-05